1, lifestyle intervention: both the quality and quantity of diet affect. High-carbohydrate diet can lead to a significant increase in postprandial blood glucose. Postprandial exercise can reduce postprandial hyperglycemia in type 2 diabetic patients, and the magnitude of the reduction is closely related to the duration and frequency of exercise, but less affects fasting blood glucose. 2, the application of hypoglycemic drugs: hypoglycemic drugs can reduce postprandial blood glucose and fasting blood glucose to varying degrees, but oral hypoglycemic drugs that mainly reduce postprandial blood glucose include alpha-glucosidase inhibitors, short-acting sulfonylurea promoters, glinephrine promoters, dipeptidyl peptidase-4 (DPP-4) inhibitors, etc. Injectable agents that mainly reduce postprandial hyperglycemia include short-acting insulin and rapid-acting insulin analogs, and short-acting glucagon-like peptide-1 (GLP-1) receptor agonists. Oral hypoglycemic agents: α-glucosidase inhibitors include acarbose, voglibose and miglitol. The addition of alpha-glucosidase inhibitors to metformin therapy improves weight comparably to GLP-1 receptor agonists. Common adverse effects are gastrointestinal reactions, such as bloating, diarrhea, nausea, and increased bowel elimination. Gastrointestinal adverse reactions can be reduced by starting with small doses and gradually increasing the dosage. Short-acting sulfonylurea pro-secretory agents, such as glipizide and glipizide. There are also glinides with similar glucose-lowering mechanism as sulfonylureas, but with faster onset of action and more obvious improvement of insulin secretion in early phase, mainly reducing PPG, including repaglinide, nateglinide and miglinide, which can also reduce postprandial hyperglycemia.